Aura Biosciences, Inc. (AURA) vs 4D Molecular Therapeutics, Inc. (FDMT)
A side-by-side comparison of Aura Biosciences, Inc. and 4D Molecular Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AURA
Aura Biosciences, Inc.
$6.12HealthcareDelayed quote: Oct 6, 2026, 1:29 PM EDT
FDMT
4D Molecular Therapeutics, Inc.
$12.66HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
Total return — AURA vs FDMT
growth of $100 · dividends reinvested · last 5yAURA -58.0% (-15.9%/yr)FDMT -46.2% (-11.7%/yr)FDMT compounded faster over this window
AURA FDMT
AURA vs FDMT: by the numbers
- •FDMT is the larger company ($662M vs $633M market cap).
- •Both run net losses; AURA's is the smaller (0.00% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | AURA | FDMT |
|---|---|---|
| P/S ratio | N/A | 7.19 |
| P/B ratio | 2.01 | 1.62 |
Profitability
| Metric | AURA | FDMT |
|---|---|---|
| Gross margin | 0.00% | 91.05% |
| Operating margin | 0.00% | -187.24% |
| Net margin | 0.00% | -194.74% |
| ROE | -41.56% | -43.95% |
| ROIC | -42.02% | -44.30% |
Growth (annualized)
| Metric | AURA | FDMT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 31.93% |
| Total return CAGR (5Y) | N/A | -13.08% |
Go deeper
Dig into the metrics
Aura Biosciences ROE4D Molecular Therapeutics ROEAura Biosciences operating margin4D Molecular Therapeutics operating marginAura Biosciences revenue growth4D Molecular Therapeutics revenue growthAura Biosciences free cash flow4D Molecular Therapeutics free cash flow
Aura Biosciences & 4D Molecular Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.